Sanofi: EU approves Supemtek as vaccine
(CercleFinance.com) - Sanofi has announced that the European Commission has approved Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older.
Supemtek is the first and only recombinant influenza vaccine approved in the EU to date. Recombinant technology allows an exact match to the key component of the influenza strains recommended by the World Health Organization, avoiding the risk of viral mutations
The first launches in Europe are expected for the 2022-23 influenza season, although is possible to increase the availability of vaccine doses for the 2021-22 season in some countries. Outside the EU, Supemtek is approved in the US.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Supemtek is the first and only recombinant influenza vaccine approved in the EU to date. Recombinant technology allows an exact match to the key component of the influenza strains recommended by the World Health Organization, avoiding the risk of viral mutations
The first launches in Europe are expected for the 2022-23 influenza season, although is possible to increase the availability of vaccine doses for the 2021-22 season in some countries. Outside the EU, Supemtek is approved in the US.
Copyright (c) 2020 CercleFinance.com. All rights reserved.